AUSTIN, Texas, April 11, 2018 (GLOBE NEWSWIRE) — Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that the company has received the 2018 Corporate Innovator Award from the National Kidney Foundation. The award will be presented to Keryx today at the NKF Spring Clinical Meetings in Austin, Texas.
“The Corporate Innovator Award was established to recognize industry partners that advance the field of nephrology by addressing an unmet medical need, or improving upon an existing practice, therapeutic or technology,” said Kevin Longino, CEO, National Kidney Foundation and a kidney transplant patient. “This year, we are recognizing Keryx Biopharmaceuticals for their work in developing innovative medicines for patients living with chronic kidney disease.”
“Keryx is a team of approximately 200 committed people working with passion to advance the care of people living with kidney disease,” said John Neylan, M.D., chief medical officer of Keryx Biopharmaceuticals. “We are honored to be recognized by the National Kidney Foundation with this award.”
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., headquartered in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of approximately 200 committed people working with passion to advance the care of people with this complex disease. This dedication has resulted in two FDA-approved indications for Keryx’s first medicine, Auryxia® (ferric citrate) tablets. For more information about Keryx, please visit www.keryx.com.
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully market Auryxia; whether we can maintain our operating expenses to projected levels while continuing our current clinical, regulatory and commercial activities; our ability to continue to supply Auryxia to the market; the risk that increased utilization by Medicare Part D subscribers will increase our gross-to-net adjustment greater than we anticipate; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
KERYX BIOPHARMACEUTICALS CONTACTAmy Sullivan, SVP, Corporate Affairs
Source: Keryx Biopharmaceuticals, Inc.